teprotumumab   Click here for help

GtoPdb Ligand ID: 10612

Synonyms: R1507 | RG-1507 | RG1507 | RV 001 | RV-001 | Tepezza® | teprotumumab-trbw
Approved drug Immunopharmacology Ligand
teprotumumab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Teprotumumab is a fully human anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody (antagonist) [2] that was originally developed in a collaboration between Genmab and Roche, and later licensed to Horizon Therapeutics who completed its advancement through clinical trials in thyroid eye disease. Heavy and light chain variable region peptide sequences for teprotumumab are 100% matches for SEQ IDs 1 and 2 (respectively) that are claimed in Hoffmann-La Roche patent WO2005005635A2 [4]. This patent claims two preferred antibodies, antibody 18 and antibody 22, but it is not clear which contains SEQ IDs 1 and 2.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2020))
International Nonproprietary Names Click here for help
INN number INN
9107 teprotumumab
Synonyms Click here for help
R1507 | RG-1507 | RG1507 | RV 001 | RV-001 | Tepezza® | teprotumumab-trbw
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 336
Other databases
GtoPdb PubChem SID 404859059
Search PubMed clinical trials teprotumumab
Search PubMed titles teprotumumab
Search PubMed titles/abstracts teprotumumab